Shajini

A passionate learner and skilled writer, Shajini serves as a Content Writer at Synopulse, delivering clear and engaging content across biopharmaceuticals and MedTech. With an MBA from Arunachala College of Engineering for Women, Shajini brings a blend of analytical expertise and creativity to simplify complex topics into impactful articles and reports.

CMS, Medicaid Expand 2026 Coverage for Five Emerging Health Technologies

by
CMS issues major 2026 reimbursement changes impacting neuromodulation, EP ablation, wound care, sleep apnea therapy, and DKD diagnostics across the U.S.

Broader 2026 Coverage Enhances Economics Across Multiple Care Settings A sweeping set of CMS and Medicaid reimbursement decisions is reshaping 2026 access across neuromodulation, electrophysiology, advanced wound reconstruction, diagnostic testing, and regenerative biologics. From APC assignments and ASC approvals to national pricing and expanded Medicaid coverage, these updates strengthen commercial readiness for emerging technologies while … Read more

France Strengthens Cancer Access with TEVIMBRA and New 14-Day Trial Fast-Track

by
France Strengthens Cancer Access with TEVIMBRA and New 14-Day Trial Fast-Track

Breaking Down TEVIMBRA Access and the 14-Day Trial Pathway France has taken two decisive steps to reinforce its clinical research ecosystem and expand access to new oncology therapies. The Haute Autorité de Santé (HAS) has issued a favourable reimbursement opinion for TEVIMBRA (tislelizumab) in gastric and oesophageal cancers, while the National Agency for the Safety … Read more

CMS Sets New Medicare 2026 Rates Across Five Innovation Categories

by
CMS Sets New Medicare 2026 Rates Across Five Innovation Categories

What the New Medicare 2026 Rates Mean for Access and Adoption The U.S. Centers for Medicare & Medicaid Services (CMS) has delivered a rare cluster of reimbursement decisions that collectively mark one of the most significant access-defining weeks of 2025. Spanning neuromodulation, molecular diagnostics, AI imaging, autoimmune disease therapy, and oncology support care, the rulings … Read more

NeuroPulse Daily: CMS Stability, PrimeC Phase 3 Approval, and Next-Gen CT Imaging Momentum

by
NeuroPulse Daily: CMS Stability, PrimeC Phase 3 Approval, and Next-Gen CT Imaging Momentum

Today’s Synopulse NeuroPulse Daily Summary highlights major shifts in neurology, from CMS reimbursement stability and pivotal trial clearances to new medtech platforms and key financing rounds, capturing the most critical regulatory, clinical, and innovation-driven movements shaping the field.

CMS Finalizes SAINT Payment Stability and Major Reimbursement Gains for NeuroPace’s RNS System

by
CMS Finalizes SAINT Payment Stability and Major Reimbursement Gains for NeuroPace’s RNS System

CMS has finalized two separate 2026 rulings benefiting neuromodulation innovators: stable outpatient reimbursement for Magnus Medical’s SAINT therapy and significant payment increases for NeuroPace’s RNS System across physician and hospital settings. The updates strengthen patient access and support broader adoption of advanced brain-health technologies.

GE HealthCare to Acquire Intelerad for $2.3B to Build a Cloud-First Enterprise Imaging Platform

by
GE HealthCare to Acquire Intelerad for $2.3B to Build a Cloud-First Enterprise Imaging Platform

GE HealthCare to Acquire Intelerad for $2.3B, Advancing a Cloud-First Imaging Strategy and Expanding Its Reach Across Ambulatory and Hospital Markets GE HealthCare has signed an agreement to acquire Intelerad for $2.3 billion in cash, a move that significantly accelerates the company’s cloud-first transformation and strengthens its position across enterprise imaging in both hospital and … Read more